Browse

XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer

DC Field Value Language
dc.contributor.authorChung, Hyun Hoon-
dc.contributor.authorKim, Mi-Kyung-
dc.contributor.authorKim, Jae Weon-
dc.contributor.authorPark, Noh-Hyun-
dc.contributor.authorSong, Yong-Sang-
dc.contributor.authorKang, Soon-Beom-
dc.contributor.authorLee, Hyo-Pyo-
dc.date.accessioned2009-11-18T08:21:55Z-
dc.date.available2009-11-18T08:21:55Z-
dc.date.issued2006-08-01-
dc.identifier.citationGynecol Oncol. 2006 Dec;103(3):1031-7. Epub 2006 Jul 27.en
dc.identifier.issn0090-8258 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16875718-
dc.identifier.urihttps://hdl.handle.net/10371/13500-
dc.description.abstractOBJECTIVES: The aim of the study was to assess whether the genetic polymorphisms were associated with the tumor response in patients treated with platinum-based neoadjuvant chemotherapy (NAC) for bulky cervical cancer. METHODS: We retrospectively reviewed the clinical data and recruited paraffin-embedded, formalin-fixed tissues of 36 patients with bulky cervical carcinoma. All patients underwent two or three cycles of platinum-based NAC followed by radical hysterectomy. We determined the genotypes of each single nucleotide polymorphism (SNP) of ERCC1, ERCC2, GGH, GSTP1, MTHFR, SLC19A1 and XRCC1 using single base primer extension assay. RESULTS: The response to platinum-based NAC was higher in patients with SNP of XRCC1 R399Q (P=0.015), and there was a significant increased chance of treatment response in women with the G/G genotype (OR 38.0; 95% CI 1.66-870.45; P=0.023). The probability of response was also higher in patients with SNP of SLC19A1 6318C/T (P=0.032). There were dose-dependent influence of the number of alleles on the response to platinum-based chemotherapy (chi2 test for linear-by-linear association; P=0.009 for XRCC1 R399Q and P=0.017 for SLC19A1 6318C/T, respectively). Moreover, the multifactor dimensionality reduction (MDR) analysis documented that the combinations of XRCC1 R399Q and GGH-401C/T genetic polymorphisms were significantly associated with response to chemotherapy (P<0.0001). CONCLUSIONS: Genetic polymorphism of XRCC1 R399Q is associated with response to platinum-based NAC in bulky cervical cancer, and MDR analysis documented association between gene-gene interaction of XRCC1 R399Q and treatment response.en
dc.language.isoenen
dc.publisherElsevieren
dc.subjectAntineoplastic Agents/*administration & dosageen
dc.subjectCarboplatin/*administration & dosageen
dc.subjectCarcinoma, Squamous Cell/drug therapy/*genetics/pathology/surgeryen
dc.subjectCisplatin/*administration & dosageen
dc.subjectDNA Primersen
dc.subjectDNA-Binding Proteins/*geneticsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectHysterectomyen
dc.subjectInfusions, Intravenousen
dc.subjectMiddle Ageden
dc.subjectNeoadjuvant Therapyen
dc.subjectNeoplasm Stagingen
dc.subjectPolymerase Chain Reactionen
dc.subject*Polymorphism, Single Nucleotideen
dc.subjectRetrospective Studiesen
dc.subjectUterine Cervical Neoplasms/drug therapy/*genetics/pathology/surgeryen
dc.titleXRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical canceren
dc.typeArticleen
dc.contributor.AlternativeAuthor정현훈-
dc.contributor.AlternativeAuthor김미경-
dc.contributor.AlternativeAuthor김재원-
dc.contributor.AlternativeAuthor박노현-
dc.contributor.AlternativeAuthor송용상-
dc.contributor.AlternativeAuthor강순범-
dc.contributor.AlternativeAuthor이효표-
dc.identifier.doi10.1016/j.ygyno.2006.06.016-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Obstetrics & Gynecology (산부인과전공)Journal Papers (저널논문_산부인과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse